May 10, 2021 7:37am

Earnings have been a drain on share pricing

Pre-open indications:  2 BUYs, 4 SELLs and 1 Maintain SELL

Earnings: uniQure NV (QURE), Voyager Therapeutics (VYGR), Precigen (PGEN)

Mentions: AGTC, AXGN, EDIT, FIXX, BSTG, CLLS, RENE.L,

My version of the morning’s “indications” is written to be informative; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  

Dow futures are UP +0.32% (+112 points), S&P futures are UP +0.11% (+5 points) and NASDAQ futures are DOWN -0.26% (-36 points)

 

Pre-market futures, the Dow and $&P were up as the Nasdaq seemed to dived again on Monday, after indexes hovered near records, last week,

European markets were mixed,

Asia-Pacific markets were trading broadly higher

 

Data Docket: The market will face a key test on Wednesday with the release of CPI inflation data.

 

Henry’omics:

U.S. stocks jumped to record levels on Friday even after a disappointing April jobs report.

Last week, the Dow rallied 2.7% to break a two-week losing streak, the S&P 500 gained 1.2%, while the Nasdaq shed 1.5%.

 

Q1/21 Earnings: <posted>: twenty-one (21) to date …  https://www.regmedinvestors.com/articles/11628

 

Friday’s evening’s recap: “earnings related advances or just an electronic trading buys on weakness?” … https://www.regmedinvestors.com/articles/11901

  • The Nasdaq closed UP +119.40 points (+0.88%);
  • The IBB closed up +$0.88% and XBI closed up +1.63%;
  • Sector volume was LOW with 4 of the 18-upside having higher than the 3-month average volume with the volume of 4 of 14-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was down -1.70 point or -9.24% at 16.69;
  • Friday’s percentage (%) of the 18-upside were +0.66% (CLBS) to +6.38% (AXGN) while the 14-downside ranges from -0.08% (FATE) to -5.57% (KDNY);

Q2/21:

May:  1 positive and 4 negative closes

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell

Biostage (BSTG) closed up +$0.02 to $1.15 with 2,364 shares traded (the “pump and promote” was back) after Thursday’s +0.02 to $1.13 with 207 shares traded after Wednesday’s -$0.01 to $1.11 with 3,032 shares traded, Tuesday’s -$0.14 to $1.12 with 249 shares traded and last Monday’s flat at $1.26 with 476 shares traded.

Question#1: Does the past cast aspersions on the reputation and integrity of Biostage (BSTG) as stock pricing continues to “fumble? Have they also forgotten that transparency has its virtues?

Question#2: WHO is still employed, especially related to the management team?

Question#3: With only $1 million left in the “till” WHAT is the runway with a “spend” and “net cash in operations of $4 million during the year ended 12/ 31/20”. Don’t forget the PPP loan remaining as DEBT ($0.4 million).

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications, from what I discern are in store:

BUY:

  • Editas Medicine (EDIT) closed down -$0.23 to $34.11 after Thursday’s -$0.38 to $34.34 and Wednesday’s +$0.06 to $34.72 with a positive +$0.15 or +0.44% pre-market indication.
  • Homology Medicine (FIXX) closed up +$0.25 to $6.51 and has a positive +$0.48 or +4.37% pre-market indication.

 

SELL:

  • Applied Genetic Technologies (AGTC) closed up +$0.01 to $3.89 after Thursday’s -$0.14 to $3.72, Wednesday’s -$0.02 to $3.86 and has a negative -$0.06 or -1.54% pre-market indication.
  • AxoGen (AXGN) closed up +$0.77 to $16.30 after Thursday’s +$2.45 and Wednesday’s +$+0.42 with a negative -$0.25 or -1.53% pre-market indication.
  • Cellectis SA (CLLS) closed UP +$0.77 to $16.30 after Thursday’s -$1.41 with a negative -$0.25 or -1.53% pre-market indication.
  • ReNeuron (RENE.L) closed down -$1.00 after Thursday’s +$1.00 after Wednesday’s +$2.00 after Tuesday’s +$7.00 and has a negative indication of -$2.35 or -1.59% pre-market indication.

 

The BOTTOM LINE: New week, and even fresher combustion factors to consider as the session advances.

it’s Friday, the length of my TOUR is over, the share pricing versus earnings “battle” will continue next

Investor expectations are NOT high during “our’ sector earnings season.

My concern, as the cell and gene therapy sector run out of buyers, it runs into trouble (just like a fire that runs out of wood).

I haven’t been wrong in seeing trouble ahead in the markets and any prognostication could be somewhat difficult or unpleasant.

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see some lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.